Granulocyte-macrophage colony-stimulating factor (GM-CSF) reduces toxoplasmastatic activity of human monocytes via induction of prostaglandin E2 (PGE2).
In this study we investigated the effect of human GM-CSF on the toxoplasmastatic activity and release of H2O2 and PGE2 by human monocytes. Incubation of monocytes from healthy controls with GM-CSF resulted in a dose-dependent reduction of toxoplasmastatic activity and a decrease in H2O2 production. Furthermore GM-CSF-treated monocytes released more PGE2 than untreated cells. To investigate the role of PGE2 in the reduced toxoplasmastatic activity of GM-CSF-treated monocytes, these cells were incubated with indomethacin. This resulted in a reduction of PGE2 release and restoration of toxoplasmastatic activity of monocytes treated with GM-CSF. GM-CSF reduces the toxoplasmastatic activity of monocytes via production of PGE2.
Delemarre
F G
FG
Department of Infectious Diseases, University Hospital, Leiden, The Netherlands.
Stevenhagen
A
A
Van Furth
R
R
D000818:Animals; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D003602:Cytotoxicity, Immunologic; D015232:Dinoprostone / Q000096:biosynthesis*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology*; D006801:Humans; D006861:Hydrogen Peroxide / Q000378:metabolism; D007111:Immunity, Cellular / Q000187:drug effects*; D007213:Indomethacin / Q000494:pharmacology; D009000:Monocytes / Q000276:immunology* / Q000469:parasitology; D014122:Toxoplasma / Q000254:growth & development* / Q000276:immunology; D014123:Toxoplasmosis / Q000276:immunology*
D016861:Cyclooxygenase Inhibitors; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006861:Hydrogen Peroxide; D015232:Dinoprostone; D007213:Indomethacin